文献速递肾移植

老年肾移植受者免疫抑制方案随机对照试验

Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial.
PubMed 文献 · J Am Soc Nephrol · 2025-11-07

OPTIMIZE 研究纳入 379 例 ≥65 岁肾移植受者,随机比较低剂量他克莫司+依维莫司+泼尼松龙(TEP)与标准剂量他克莫司+吗替麦考酚酯+泼尼松龙(TMP)。2 年成功移植率 TEP 组 50%、TMP 组 57%,差异无统计学意义;患者生存和移植物生存亦无显著差异。

要点

  • 低剂量 TEP 方案未提高老年肾移植受者 2 年成功移植率。
  • TEP 与 TMP 在患者生存和移植物生存上无显著差异。
  • TEP 未带来更好的肾功能或更少的感染。

核心结论

  • 与标准剂量 TMP 相比,低剂量 TEP 方案未提高老年肾移植受者成功移植率。

研究设计与样本

  • OPTIMIZE 为随机临床试验,纳入 379 例年龄 ≥65 岁的肾移植受者。
  • 按供肾来源分层:A 层为 >65 岁 deceased donor 供肾(198 例),B 层为 <65 岁 deceased donor 或活体供肾(181 例)。

主要发现

  • 2 年成功移植率 TEP 组 94 例(50%),TMP 组 110 例(57%),差异 7%(95%CI -17 至 3),P=0.91。
  • 患者生存 TEP 组 167 例(89%),TMP 组 171 例(89%),P=0.95。
  • 移植物生存 TEP 组 155 例(83%),TMP 组 162 例(84%),P=0.65。
  • A 层和 B 层内各终点均无显著差异。

关键数值与推荐

  • TEP 组他克莫司目标谷浓度:0-3 月 5-7 ng/ml,3-6 月 2-4 ng/ml,6 月后 1.5-4 ng/ml。
  • TMP 组他克莫司目标谷浓度:0-3 月 8-12 ng/ml,3-6 月 6-10 ng/ml,6 月后 5-8 ng/ml。
  • 依维莫司目标谷浓度 3-6 µg/L。
  • 成功移植定义:2 年时存活且移植物有功能,eGFR 高于预设阈值(A 层 30,B 层 45 ml/min per 1.73 m²)。

临床怎么用

  • 老年肾移植受者采用低剂量 TEP 方案未显示优于标准 TMP 方案。
  • 临床决策仍需结合个体情况选择免疫抑制方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Low-dose tacrolimus, everolimus, and prednisolone did not result in a higher rate of successful transplantation in older kidney transplant recipients. Low-dose tacrolimus, everolimus, and prednisolone did not result in better kidney function or fewer infections in older kidney transplant recipients. BACKGROUND: We hypothesized that older kidney transplant recipients receiving low-dose tacrolimus, everolimus, and prednisolone (TEP) have better outcomes than patients receiving standard-dose tacrolimus, mycophenolate mofetil, and prednisolone (TMP). METHODS: The OPTIMIZE study was a randomized clinical trial in kidney transplant recipients age ≥65 years. Patients receiving a kidney from a deceased donor older than 65 years (stratum A) or a kidney from a deceased donor younger than 65 years or a living donor (stratum B) were included. Patients were randomized to TEP or TMP groups. Tacrolimus target trough levels in the TEP group were 5-7 ng/ml until 3 months, 2-4 ng/ml from 3 to 6 months, and 1.5-4 ng/ml from 6 months onwards. Tacrolimus target trough levels in the TMP group were 8-12, 6-10, and 5-8 ng/ml. Everolimus target trough levels were 3-6 µ g/L. The primary end point of successful transplantation was defined as being alive with a functioning graft with an eGFR above a predefined threshold at 2 years after transplantation. Predefined eGFR thresholds were 30 (stratum A) or 45 ml/min per 1.73 m 2 (stratum B). RESULTS: A total of 379 patients were randomized, of whom 198 were in stratum A (TEP 97, TMP 101) and 181 in stratum B (TEP 90, TMP 91). The median trough levels for everolimus and tacrolimus were within the target range throughout the study. There was no statistically significant difference in successful transplantation at 2 years between the groups (TEP 94 [50%], TMP 110 [57%]; difference 7% [95% confidence interval, -17 to 3] P = 0.91). Regarding the predefined secondary outcomes, patient survival (TEP 167 [89%], TMP 171 [89%]; P = 0.95) and graft survival (TEP 155 [83%], TMP 162 [84%]; P = 0.65) did not differ significantly. Within strata A and B, there were no significant differences in the end points. CONCLUSIONS: Immunosuppression with low-dose tacrolimus, everolimus, and prednisolone did not result in a higher rate of successful transplantation in de novo older kidney transplant recipients compared with immunosuppression with standard-dose TMP. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT03797196 .

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Sanders JF, de Boer SE, Jonker J, et al. Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial. J Am Soc Nephrol. 2025. PMID: 41201871. doi:10.1681/ASN.0000000924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。